Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How Patients Must Have H3 K27M Tumor Mutation for Clinical Trial with ONC201. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.
Patients Must Have H3 K27M Tumor Mutation for Clinical Trial with ONC201
